News Search Results
Feb 18, 2026, 08:15 ET RoviSys Advances Regulated Industry Facilities Strategy, Names Chris Kulbago Director
discrete manufacturing automation solutions, is pleased to reaffirm its expanded facilities systems integration capabilities for pharmaceutical, biotechnology, and medical device manufacturers. As regulatory expectations increase and facilities become more complex, manufacturers require reliable and integrated
More news about: RoviSys
Feb 18, 2026, 08:00 ET Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture
More news about: Ginkgo Bioworks
Feb 18, 2026, 07:00 ET Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System
Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a license agreement to support Finding Hope for
More news about: Apertura Gene Therapy
Feb 18, 2026, 06:59 ET Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 17, 2026, 16:05 ET Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously
More news about: Immunic, Inc.
Feb 17, 2026, 16:01 ET HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
manufacturing and R&D investment.Technological Innovation and Enhanced Biomanufacturing EfficiencyAdvancements in biotechnology are another significant driver of market growth. Improved methods for synthesizing high-activity growth factors and integration of quality-by-design
More news about: Persistence Market Research Pvt. Ltd.
Feb 17, 2026, 11:32 ET Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14,
More news about: Moonage Media
Feb 17, 2026, 11:23 ET AI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 | Valuates Reports
https://reports.valuates.com/request/sample/QYRE-Auto-21X19811/Global_AI_in_Biotechnology_Market What are the key factors driving the growth of AI in the Biotechnology Market?● AI in biotechnology is being shaped by platform-driven
More news about: Valuates Reports
Feb 17, 2026, 10:45 ET 2D Materials Market Surges to USD 10.2 Billion by 2033, Propelled by 15.8% CAGR - Verified Market Reports®
Electronics and SemiconductorsEnergy and PowerAerospace and DefenseAutomotiveHealthcare and BiotechnologyBy FunctionalityThermal ConductivityElectrical ConductivityMechanical StrengthOptical
More news about: Verified Market Reports
Feb 17, 2026, 09:01 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., Feb. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall
More news about: MetaVia Inc.
Feb 17, 2026, 09:00 ET Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that the independent Data Safety
More news about: Diakonos Oncology
Feb 17, 2026, 09:00 ET BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San
More news about: BioMarin Pharmaceutical Inc.
Feb 17, 2026, 08:30 ET Amorphical to Present Long-Term Phase 2 Crohn's Disease Data at the 21st Congress of ECCO
United States.About AmorphicalAmorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims
More news about: Amorphical
Feb 17, 2026, 08:00 ET Resurrect Bio announces $8.1M initial close of Series A led by Corteva
LONDON, Feb. 17, 2026 /PRNewswire/ -- Resurrect Bio, a biotechnology company revolutionizing agriculture by equipping crops with genetic defenses against disease, today announced the successful initial closing of its Series
More news about: Resurrect Bio
Feb 17, 2026, 08:00 ET GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
17, 2026 /PRNewswire/ -- GelMEDIX, Inc., a biotechnology company developing regenerative therapies to restore vision, announced today the completion of a $13 million seed financing led by Safar Partners, with participation from HTL Biotechnology, Beacon Angels, TiE Boston Angels, Boston Harbor Angels,
More news about: GelMEDIX
Feb 17, 2026, 07:30 ET Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange
More news about: Palatin Technologies, Inc.
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
million people in the U.S. currently have MS.2About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 17, 2026, 06:59 ET Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5
More news about: Q32 Bio
Feb 17, 2026, 02:25 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.Details of the case: Inovio describes itself as a "biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 16, 2026, 10:46 ET Genotyping Market to Reach $61.6 Billion by 2033 Globally, at 13.8% CAGR: Allied Market Research
Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, and Others), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, and Others):
More news about: Allied Market Research
Feb 16, 2026, 10:01 ET Pyrogen Testing Market to Reach $3.6 billion, Globally, by 2033 at 8.4% CAGR: Allied Market Research
that aligns closely with human physiology.The pharmaceutical and biotechnology companies segment to maintain its lead position during the forecast period By end user, the pharmaceutical and biotechnology companies segment accounted for the largest share in 2022, contributing to
More news about: Allied Market Research
Feb 16, 2026, 10:00 ET Lilly to participate in TD Cowen's 46th Annual Health Care Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 16, 2026, 08:00 ET USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company